

## 20. ELN Symposium with 23. KNL Symposium

Congress Center Rosengarten, Mannheim, April 9, 2024, 8:00-20:00

	<b>Sessions 1-4 (Mahler 1)</b>	<b>Chairs/Contributors</b>
<b>8:00 - 9:30</b>	<b>Session 1: WP5 AML 1</b>	<b>C. Röllig, G. Huls</b>
30'	Update RESOLVE EU Project	M. Heuser
30'	Update IMPACT EU Project	G. Marconi
15'	ELN Position Paper on Fitness in AML	A. Venditti
15'	Open forum for discussion and future projects	All
9:30 - 9:45	Coffee Break	
<b>9:45 - 11:15</b>	<b>Session 2: WP5 AML 2 (Emerging therapies)</b>	<b>C. Röllig, G. Huls</b>
	Update European Academic AML trials and Registries	
10'	PETHEMA	P. Montesinos
10'	PALG	A. Wierzbowska
10'	ALFA	H. Dombret
10'	FILO	C. Recher
10'	NCRI	C. Craddock
10'	GIMEMA	A. Venditti
10'	HOVON-AMLSG	G. Ossenkoppele
10'	SAL-AML CG	C. Röllig
10'	Discussion on joint future projects	All
11:15 - 11:30	Break	
<b>11:30 - 13:00</b>	<b>Session 3: HARMONY Alliance Foundation</b>	<b>J.M. Hernández</b>
15'	Established operational model and tools for clinicians & researchers	J.M. Hernández
40'	Progress of the AML Research Projects:	
	Secondary AML and Long-Term Outcome of 1296 pts with nd APL	L. Bullinger
	Dirichlet's calculations of genetic risk	A. Turki
	The impact of gender on genetic aberrations and clinical outcome	J. Tettero
	Individualized prediction of Adult AML outcome by machine learning	A. Hernández
30'	Progress of the ALL, MDS, and CML Projects:	
	Real-world evaluation of UK high hyper diploidy profile	A. Enshaei
	Exploring treatment patterns and outcomes in older adult B-ALL	A. Turki
	CML Genomics project	A. Albeer
	QoL in CML projects	E. González
5'	The HARMONY Alliance Foundation:	
	Next steps. Fostering global data sharing in hematology	K. Döhner
13:00 - 14:00	Lunch	
<b>14:00 - 15:30</b>	<b>Session 4: WP8 MDS</b>	<b>L. Malcovati, M. Mittelman</b>
3'	Introduction	L. Malcovati
15'	Report EUMDS Registry	M. Mittelman
15'	MDS diagnosis using PB	L. Shlush
15'	MDS Hub-update - international guideline development	L. Malcovati
15'	ELN iMDS Flow Working Group	
	- ELN recommendations of flow cytometry in MDS 2023	A. van de Loosdrecht
15'	Progress of the European Trial Platform:	
	- Recent achievements and current perspective	U. Platzbecker
12'	General discussion and closure	L. Malcovati, M. Mittelman

## Sessions 5-8 (Mahler 2)

## Chairs/Contributors

<b>8:00 - 9:30</b>	<b>Session 5: WP17 Biometry and Epidemiology</b>	<b>M. Pfirrmann, M. Lauseker</b>
20'	Multiple imputation	M. Lauseker
20'	Endpoints / estimands when the PH assumption does not hold	I. Azzali
20'	Safety first: Strategies against biased analysis of adverse event data	T. Lang
20'	interpreting the EURO-SKI study and its TFR outcome	M. Pfirrmann
10'	Questions and answers	
9:30 - 9:45	Coffee Break	
<b>9:45 - 11:15</b>	<b>Session 6: WP4 CML</b>	<b>L. Stenke, A. Hochhaus</b>
15'	Life expectancy of Swedish CML patients	E. Yi-Tung
15'	QoL analyses for CML patients at baseline, nilotinib vs nilo + peg-IFN	M. Lorch
15'	Prediction of response to asciminib according to BCR::ABL1 mutations and variants. An EUTOS project.	O. Hantschel
15'	Validation of risk scores for pediatric CML patients	F. Millot
15'	Dasatinib holidays for improved tolerability: Final analysis of the DasaHit study	A. Hochhaus
15'	ELN recommendations for treating CML 2024	J. Apperley
11:15 - 11:30	Break	
<b>11:30 - 13:00</b>	<b>Session 7: WP9 MPN</b>	<b>T. Barbui, M. Griesshammer</b>
10'+2'	Non canonical variants in MPN: friend or foe? MPN-OLIVETTI registry	G. Carreño
10'+2'	Developing novel composite endpoints for myelofibrosis trials: the DEMYO –ELN project	M. Marchetti
10'+2'	BCR/ABL negative MPN in pregnancy, ELN Recommendations	M. Griesshammer
10'+2'	ELN registry in myelofibrosis “ERNEST-3”	T. Barbui
10'+2'	MPL-mutant and triple-negative essential thrombocythemia – a collaborative ELN project	S. Koschmieder
10'+2'	Facilitating clinical trials in polycythemia vera: machine learning to identify patient cohorts at high near-term risk of thrombosis	J. Scandura
10'+2'	- Titel to follow -	D. Royston
13:00 - 14:00	Lunch	
<b>14:00 - 15:30</b>	<b>Session 8: WP14 Transplantation</b>	<b>D. Niederwieser, W. Jędrzejczak, T. Ruutu</b>
	Completed projects:	
5'	Oral at EBMT: Randomized study in elderly AML, HCT vs. CT	D. Niederwieser
5'	Global transplant registry: a center and internet-based survey of cellular therapies with more than 800.000 reports	D. Neumann
5'	Help for Ukrainian hematology patients – a global initiative supporting the establishment of hematology centers and HCT programs in a time of war	I. Korenks
	Current projects:	
5'	Waustim maintenance lenalidomide results	L. Gardaret
10'	Substudies of the Waustim project	L. Gardaret
5'	Developments in the clinical assessment of VOD/SOS	T. Ruutu
10'	Global transplant survey up to 2018 (manuscript)	Y. Atsuta
5'	R/R AML: HCT protocols	G. Marconi
10'	GvHD app	D. Neumann
5'	ELN Recommendations for treating CML	D. Niederwieser
	New projects:	
5'	Worldwide utilization of HCT in CML + outcome registry	all
5'	Worldwide utilization of AML outcome registry	all
10'	AI; GvHD recommendations	all
5'	Pediatric registry	all

## Sessions 9-12 (Mahler 3)

8:00 - 9:30

### Session 9: WP6 ALL

- 10' Combination of optimal genomic mapping (OGM) and NGS to improve the diagnosis of patients with B-other ALL
- 10' Interaction between optical genomic mapping and digital Multiplex ligation-dependent probe amplification (MLPA)
- 10' Long-term follow up of the PONALFIL Trial for adult patients with de novo Ph+ALL
- 10' Can we stop TKI Treatment in Ph+ ALL?
- 10' Developmental trajectories and cooperation genomic events define molecular subtypes of BCR::ABL1-positive ALL
- 10' GMALL BOLD (Sequential Dose Reduced Chemotherapy and Blinatumomab) trial
- 10' Ponatinib for R/R Ph-like ALL: results from a compassionate use program
- 10' 2023 ELN Recommendations for ALL in adults: Diagnosis, Prognostic Factors and Assessment. Management

9:30 - 9:45

Coffee Break

9.45 – 11.15

### Session 10: WP10 Immunophenotyping

- Morphology
- Update on AML NOS
  - Digital morphology for bone marrow aspirates
- Flow cytometry
- Update on MPAL
  - Immunophenotypic changes after B-cell targeted therapies (bispecifics and CAR T-cells)

Break

11:30 - 13:00

### Session 11: WP11 Cytogenetics

- 18' Optical Genome Mapping in AML and B-ALL diagnosis
- 18' The role of cytogenetics in precursor lesions (CHIP, CCUS)
- 18' Utility of peripheral blood for mutational analysis in patients with confirmed or suspected MDS
- 18' Cytogenetically visible and invisible fusion genes in MLN-TK
- 18' Update on the use of AI in chromosome banding analysis

13:00 - 14:00

Lunch

14:00 - 15:30

### Session 12: WP12/13 MRD/NGS

How we define and clinically use MRD in hematologic malignancies

- 10'+5' AML
- 10'+5' ALL
- 10'+5' CLL
- 10'+5' CML
- 10'+5' MM
- 10'+5' Clinical Trials

## Session 13 (Seminarraum 3.9)

11:30 - 13:00

### Session 13: WP7 CLL/ERIC

- 15' Introduction to the RESOLVE project and update
- 30' Study design and timeline
- 30' MRD-assessment: Technical aspects
- 15' Discussion

## Chairs/Contributors

S. Chiaretti, D. Hoelzer

J.-M. Hernandez-Rivas

G. La Pietra

J.-M. Ribera

M. Dragani

T. Beder

N. Gökbüget

F. Kaiser

N. Gökbüget

M.C. Béné, G. Zini

G. Zini

G. Zini

M.C. Béné

A. Dunlop

I. Summerer, B. Espinet

K. Rack

G. Hörmann

S. Huber

G. Metzgeroth

I. Summerer

C. Thiede, M. Heuser, T. Haferlach

M. Heuser

M. Brüggemann

A. Rawstron

A. Hochhaus

A. Rawstron

P. Ramos

## Chairs/Contributors

P. Ghia

P. Ghia

L. Scarfò

A. Rawstron

K. Stamatopoulos

13:00 – 14:00 Luncheon poster walk (Foyer)

R. Gale

### Plenary Sessions (Mahler1)

16:00 - 17:30 Session 14: General Assembly and Summary reports

R. Hehlmann, D. Niederwieser

20' General Assembly  
5' WP5 AML 1  
5' WP5 AML 2  
5' HARMONY  
5' WP8 MDS  
5' WP17 (Statistics)  
5' WP4 (CML)  
5' WP9 (MPN)  
5' WP14 (Transplantation)  
5' WP6 (ALL)  
5' WP10 (Immunophenotyping)  
5' WP11 (Cytogenetics)  
5' WP12/13 (MRD, NGS)  
5' WP7 CLL

R. Hehlmann  
G. Huls  
C. Röllig  
J. Hernandez  
L. Malcovati  
M. Pfirrmann  
A. Hochhaus  
T. Barbui  
D. Niederwieser  
D. Hoelzer  
M. Béné  
I. Summerer  
C. Thiede  
P. Ghia

17:30-17:45 ELN Merit Awards/KNL Verdienstzertifikate

Derek MacLennan  
Nicola Gökbuget  
Stephan Pichl

Introducer

G. Ossenkoppele  
D. Hoelzer  
R. Hehlmann

17:45 - 18:00 Break with Group photo

18:00 - 20:00 Session 15: Keynote lectures

R. Hehlmann, D. Hoelzer

20' ELN Laboratory Recommendations for managing CML  
20' HARMONY dashboard for hematologic malignancies  
20' 20 years cooperative research on MPNs in ELN-WP9  
20' ELN recommendations on infections in leukemias  
20' 25 years cooperative research on ALL within KNL and ELN-WP6  
20' 20 years AML in ELN WP5: was it worthwhile?

S. Soverini  
A. Hernandez  
T. Barbui  
P. Ljungman  
D. Hoelzer  
G. Ossenkoppele

20:00 Working dinner in the foyer



**ELN** Foundation  
European ■ LeukemiaNet



**DFG**